Rocket Pharmaceuticals, Inc. (RCKT): Price and Financial Metrics
GET POWR RATINGS... FREE!
RCKT Stock Price Chart Interactive Chart >
RCKT Price/Volume Stats
|Current price||$15.96||52-week high||$36.87|
|Prev. close||$14.04||52-week low||$7.57|
|Day high||$16.02||Avg. volume||737,997|
|50-day MA||$15.45||Dividend yield||N/A|
|200-day MA||$15.41||Market Cap||1.05B|
Rocket Pharmaceuticals, Inc. (RCKT) Company Bio
Rocket Pharmaceuticals, Inc., formerly Inotek Pharmaceuticals Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies for glaucoma and other diseases of the eye.
Most Popular Stories View All
RCKT Latest News Stream
|Loading, please wait...|
RCKT Latest Social Stream
View Full RCKT Social Stream
Latest RCKT News From Around the Web
Below are the latest news stories about ROCKET PHARMACEUTICALS INC that investors may wish to consider to help them evaluate RCKT as an investment opportunity.
CRANBURY, N.J., September 27, 2022--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a leading late-stage, clinical biotechnology company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders with high unmet need, today announces that Gaurav Shah, M.D., Chief Executive Officer, will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on Tuesday, Oct. 4, at 2:00 p.m. ET, at the Westin Hotel in New York City. Management wil
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT) and Treace Medical Concepts (TMCI)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Rocket Pharmaceuticals (RCKT – Research Report) and Treace Medical Concepts (TMCI – Research Report) with bullish sentiments. Rocket Pharmaceuticals (RCKT) In a report released today, Gil Blum from Needham maintained a Buy rating on Rocket Pharmaceuticals, with a price target of $62.00. The company's shares closed last Tuesday at $13.69. According to TipRanks.
In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Rocket Pharmaceuticals (RCKT - Research Report), with a price target of $62.00. The company's shares opened today at $13.70.According to TipRanks, Livshits is a 5-star analyst with an average return of 23.6% and a 39.94% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Meiragtx Holdings, and Rocket Pharmaceuticals.Rocket Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $46.25.See the top stocks recommended by analysts >>The company has a one-year high of $36.87 and a one-year low of $7.57.
Shares of Renovacor (NYSE: RCOR) were up in early morning trading on Tuesday following the news of its acquisition by Rocket Pharmaceuticals (RCKT). Rocket will acquire Renovacor in an all-stock deal for $2.60 per share, based on the volume-weighted average trading price of Rocket stock priced at $15.51 for the 30 trading days through and including Monday, September 19. Renovacor is a biotechnology company focused on delivering innovative precision therapies for genetic cardiovascular diseases. As a part of this deal, Renovacor shareholders will receive around 0.1676 shares of Rocket in exchange for each of their shares in Renovacor and upon the close of the transaction, will own approximately 4.
Renovacor (RCOR) stock is gaining on Tuesday after announcing that Rocket Pharmaceuticals (RCKT) is acquiring it in an all-stock deal.
RCKT Price Returns